{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T20:44:37Z","timestamp":1793565877620,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673724"],"award-info":[{"award-number":["81673724"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002865","name":"Chongqing Science and Technology Commission","doi-asserted-by":"publisher","award":["cstc2018jxjl130084"],"award-info":[{"award-number":["cstc2018jxjl130084"]}],"id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002865","name":"Chongqing Science and Technology Commission","doi-asserted-by":"publisher","award":["cstc2018jxjl130007"],"award-info":[{"award-number":["cstc2018jxjl130007"]}],"id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002865","name":"Chongqing Science and Technology Commission","doi-asserted-by":"publisher","award":["cstc2018jxj1130016"],"award-info":[{"award-number":["cstc2018jxj1130016"]}],"id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chongqing Municipal Health and Health Committee","award":["ZY20181009"],"award-info":[{"award-number":["ZY20181009"]}]},{"name":"Chongqing Hospital of Traditional Chinese Medicine Advantageous Diseases Special Fund","award":["cqszyyysbz2018004"],"award-info":[{"award-number":["cqszyyysbz2018004"]}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.biopha.2019.109704","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T16:40:14Z","timestamp":1577724014000},"page":"109704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Molecular mechanisms and clinical application of Iguratimod: A review"],"prefix":"10.1016","volume":"122","author":[{"given":"Huihui","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2019.109704_bib0005","article-title":"The clinicopathologic significance of inflammasome activation in autoimmune diseases","author":"Kahlenberg","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.biopha.2019.109704_bib0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1586\/1744666X.2015.1027151","article-title":"Iguratimod for the treatment of rheumatoid arthritis in Japan","volume":"11","author":"Tanaka","year":"2015","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2019.109704_bib0015","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1254\/jjp.67.305","article-title":"T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts","volume":"67","author":"Tanaka","year":"1995","journal-title":"Jpn. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.biopha.2019.109704_bib0020","first-page":"2591","article-title":"Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells","volume":"28","author":"Kohno","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.biopha.2019.109704_bib0025","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/356040","article-title":"Regulatory effect of iguratimod on the balance of Th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis","volume":"2015","author":"Xu","year":"2015","journal-title":"Mediators Inflamm."},{"issue":"4","key":"10.1016\/j.biopha.2019.109704_bib0030","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3892\/ijmm.2013.1468","article-title":"Kaempferol inhibits IL-1beta-induced proliferation of rheumatoid arthritis synovial fibroblasts and the production of COX-2, PGE2 and MMPs","volume":"32","author":"Yoon","year":"2013","journal-title":"Int. J. Mol. Med."},{"issue":"7","key":"10.1016\/j.biopha.2019.109704_bib0035","first-page":"935","article-title":"Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-o ne. 1st communication: antiinflammatory, analgesic and other related properties","volume":"42","author":"Tanaka","year":"1992","journal-title":"Arzneimittelforschung"},{"issue":"11","key":"10.1016\/j.biopha.2019.109704_bib0040","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/rheumatology\/keg381","article-title":"Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice","volume":"42","author":"Tanaka","year":"2003","journal-title":"Rheumatology Oxford (Oxford)"},{"issue":"4","key":"10.1016\/j.biopha.2019.109704_bib0045","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10875-011-9542-6","article-title":"Combined treatment of etanercept and MTX reverses Th1\/Th2, Th17\/Treg imbalance in patients with rheumatoid arthritis","volume":"31","author":"Lina","year":"2011","journal-title":"J. Clin. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2019.109704_bib0050","doi-asserted-by":"crossref","first-page":"8200","DOI":"10.3892\/mmr.2017.7648","article-title":"Iguratimod prevents ovariectomyinduced bone loss and suppresses osteoclastogenesis via inhibition of peroxisome proliferatoractivated receptorgamma","volume":"16","author":"Wu","year":"2017","journal-title":"Mol. Med. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2019.109704_bib0055","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0006-291X(02)02754-7","article-title":"A novel anti-rheumatic drug, T-614, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein-2-induced bone formation in vivo","volume":"299","author":"Kuriyama","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2019.109704_bib0060","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/1756-185X.13463","article-title":"Iguratimod ameliorates bleomycin-induced alveolar inflammation and pulmonary fibrosis in mice by suppressing expression of matrix metalloproteinase-9","volume":"22","author":"Zhao","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2019.109704_bib0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00228-017-2342-z","article-title":"A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers","volume":"74","author":"Xiao","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2019.109704_bib0070","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00029330-200804010-00008","article-title":"Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial","volume":"121","author":"Lu","year":"2008","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"10.1016\/j.biopha.2019.109704_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/s10165-006-0542-y","article-title":"Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study","volume":"17","author":"Hara","year":"2007","journal-title":"Mod. Rheumatol."},{"issue":"6","key":"10.1016\/j.biopha.2019.109704_bib0080","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/rheumatology\/39.6.655","article-title":"A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis","volume":"39","author":"Emery","year":"2000","journal-title":"Rheumatology Oxford (Oxford)"},{"issue":"3","key":"10.1016\/j.biopha.2019.109704_bib0085","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/s10165-012-0724-8","article-title":"Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Ishiguro","year":"2013","journal-title":"Mod. Rheumatol."},{"issue":"3","key":"10.1016\/j.biopha.2019.109704_bib0090","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/14397595.2013.843756","article-title":"Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial","volume":"24","author":"Hara","year":"2014","journal-title":"Mod. Rheumatol."},{"issue":"1","key":"10.1016\/j.biopha.2019.109704_bib0095","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3109\/s10165-006-0543-x","article-title":"Long-term safety study of iguratimod in patients with rheumatoid arthritis","volume":"17","author":"Hara","year":"2007","journal-title":"Mod. Rheumatol."},{"issue":"7","key":"10.1016\/j.biopha.2019.109704_bib0100","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/1756-185X.12754","article-title":"APLAR rheumatoid arthritis treatment recommendations","volume":"18","author":"Lau","year":"2015","journal-title":"Int. J. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2019.109704_bib0105","first-page":"292","article-title":"Experimental study on the in vitro intervention of Iguratimod on synovial cells of rheumatoid arthritis","volume":"44","author":"Wang","year":"2015","journal-title":"SHAANXI YIXUE ZAZHI"},{"issue":"4","key":"10.1016\/j.biopha.2019.109704_bib0110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/PL00000291","article-title":"An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation","volume":"51","author":"Aikawa","year":"2002","journal-title":"Inflamm. Res."},{"issue":"5","key":"10.1016\/j.biopha.2019.109704_bib0115","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11926-009-0052-y","article-title":"The role of interleukin-17 in the pathogenesis of rheumatoid arthritis","volume":"11","author":"Gaffen","year":"2009","journal-title":"Curr. Rheumatol. Rep."},{"issue":"7","key":"10.1016\/j.biopha.2019.109704_bib0120","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.cellsig.2010.11.022","article-title":"Signaling of interleukin-17 family cytokines in immunity and inflammation","volume":"23","author":"Chang","year":"2011","journal-title":"Cell. Signal."},{"key":"10.1016\/j.biopha.2019.109704_bib0125","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1600-065X.2008.00648.x","article-title":"The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis","volume":"223","author":"Noss","year":"2008","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2019.109704_bib0130","article-title":"Study on the regulatory effects of IGU on CD3+T cells and cytokines il-6 in patients with rheumatoid arthritis","volume":"30","author":"MT W","year":"2015","journal-title":"Chin J Ctrl Endem Dis"},{"issue":"10","key":"10.1016\/j.biopha.2019.109704_bib0135","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.4049\/jimmunol.1300832","article-title":"A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide","volume":"191","author":"Luo","year":"2013","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2019.109704_bib0140","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1365-2567.2008.02879.x","article-title":"Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells","volume":"126","author":"Stojanovic","year":"2009","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.biopha.2019.109704_bib0145","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1074\/jbc.275.1.444","article-title":"Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis","volume":"275","author":"Onodera","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2019.109704_bib0150","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.lfs.2018.08.038","article-title":"Molecular mechanisms of glucocorticoid resistance in systemic lupus erythematosus: a review","volume":"209","author":"Gao","year":"2018","journal-title":"Life Sci."},{"issue":"51","key":"10.1016\/j.biopha.2019.109704_bib0155","doi-asserted-by":"crossref","first-page":"26502","DOI":"10.1074\/jbc.M116.743328","article-title":"Identification of iguratimod as an inhibitor of macrophage migration inhibitory factor (MIF) with steroid-sparing potential","volume":"291","author":"Bloom","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.biopha.2019.109704_bib0160","first-page":"6","article-title":"Modulation of Th17 cells and Treg cell imbalance in patients with rheumatoid arthritis by Iguratimod","volume":"31","author":"Wang","year":"2018","journal-title":"Chinese Journal of Medical Equipment"},{"issue":"7","key":"10.1016\/j.biopha.2019.109704_bib0165","doi-asserted-by":"crossref","first-page":"A772","DOI":"10.1016\/j.jval.2014.08.321","article-title":"The research of effects of iguratimod(T-614) on the apoptosis of peripheral blood mononuclear cell and TH1 in rheumatoid arthritis","volume":"17","author":"Liu","year":"2014","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.biopha.2019.109704_bib0170","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrneph.2016.20","article-title":"Plasma cells as an innovative target in autoimmune disease with renal manifestations","volume":"12","author":"Hiepe","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"issue":"10","key":"10.1016\/j.biopha.2019.109704_bib0175","doi-asserted-by":"crossref","first-page":"e108273","DOI":"10.1371\/journal.pone.0108273","article-title":"Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL\/lpr mice","volume":"9","author":"Yan","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2019.109704_bib0180","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13075-019-1874-2","article-title":"Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC\/EGR1 axis","volume":"21","author":"Ye","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2019.109704_bib0185","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/ar2554","article-title":"T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis","volume":"10","author":"Du","year":"2008","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2019.109704_bib0190","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1074\/jbc.M704724200","article-title":"BMP-2 induces Osterix expression through up-regulation of Dlx5 and its phosphorylation by p38","volume":"283","author":"Ulsamer","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2019.109704_bib0195","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4901591","article-title":"T-614 promotes osteoblastic cell differentiation by increasing Dlx5 expression and regulating the activation of p38 and NF-kappaB","volume":"2018","author":"Song","year":"2018","journal-title":"Biomed Res. Int."},{"issue":"6","key":"10.1016\/j.biopha.2019.109704_bib0200","first-page":"1049","article-title":"Honokiol stimulates osteoblastogenesis by suppressing NF-kappaB activation","volume":"28","author":"Yamaguchi","year":"2011","journal-title":"Int. J. Mol. Med."},{"issue":"2","key":"10.1016\/j.biopha.2019.109704_bib0205","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.biopha.2019.109704_bib0210","doi-asserted-by":"crossref","first-page":"44","DOI":"10.14715\/cmb\/2016.62.13.8","article-title":"Effect of iguratimod and methotrexate on RANKL and OPG expression in serum and IL-1beta-induced fibroblast-like synoviocytes from patients with rheumatoid arthritis","volume":"62","author":"Wang","year":"2016","journal-title":"Cell. Mol. Biol. (Noisy-le-grand)"},{"issue":"32","key":"10.1016\/j.biopha.2019.109704_bib0215","first-page":"4530","article-title":"Clinical observation of iguratimod combined with methotrexate in the treatment of rheumatoid arthritis","volume":"28","author":"Ren","year":"2017","journal-title":"China Pharmacy"},{"key":"10.1016\/j.biopha.2019.109704_bib0220","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.intimp.2016.03.038","article-title":"Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-kappaB and MAPK pathways","volume":"35","author":"Gan","year":"2016","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2019.109704_bib0225","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.intimp.2012.03.003","article-title":"T-614 alters the production of matrix metalloproteinases (MMP-1 andMMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro","volume":"13","author":"Du","year":"2012","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2019.109704_bib0230","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/ard.2009.126573","article-title":"Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA","volume":"69","author":"Nam","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2019.109704_bib0235","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/214683","article-title":"Inhibitory effect of a novel antirheumatic drug T-614 on the IL-6-Induced RANKL\/OPG, IL-17, and MMP-3 expression in synovial fibroblasts from rheumatoid arthritis patients","volume":"2015","author":"Wei","year":"2015","journal-title":"Biomed Res. Int."},{"issue":"1","key":"10.1016\/j.biopha.2019.109704_bib0240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1755-1536-5-11","article-title":"Molecular and cellular mechanisms of pulmonary fibrosis","volume":"5","author":"Todd","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"4","key":"10.1016\/j.biopha.2019.109704_bib0245","first-page":"317","article-title":"Time course of matrix metalloproteases and tissue inhibitors in bleomycin-induced pulmonary fibrosis","volume":"50","author":"Oggionni","year":"2006","journal-title":"Eur. J. Histochem."},{"issue":"1","key":"10.1016\/j.biopha.2019.109704_bib0250","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1381612033392341","article-title":"Re-evaluation of fibrogenic cytokines in lung fibrosis","volume":"9","author":"Kelly","year":"2003","journal-title":"Curr. Pharm. Des."},{"issue":"5","key":"10.1016\/j.biopha.2019.109704_bib0255","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/14397595.2016.1265695","article-title":"Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan","volume":"27","author":"Mimori","year":"2017","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.biopha.2019.109704_bib0260","first-page":"55","article-title":"Value analysis of Iguratimod treatment in patients with rheumatoid arthritis","volume":"3","author":"Li","year":"2018","journal-title":"Clin. Med."},{"issue":"9","key":"10.1016\/j.biopha.2019.109704_bib0265","first-page":"127","article-title":"Effect of Iguratimod on serum TNF-\u03b1 and VEGF levels in patients with refractory rheumatoid arthritis","volume":"37","author":"Yang","year":"2017","journal-title":"Clin. Med."},{"issue":"2","key":"10.1016\/j.biopha.2019.109704_bib0270","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/14397595.2014.938401","article-title":"Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis","volume":"25","author":"Okamura","year":"2015","journal-title":"Mod. Rheumatol."},{"issue":"3","key":"10.1016\/j.biopha.2019.109704_bib0275","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/14397595.2018.1481565","article-title":"Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-kappaB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years\u2019 treatment for Japanese rheumatoid arthritis patients","volume":"29","author":"Ishikawa","year":"2019","journal-title":"Mod. Rheumatol."},{"issue":"2","key":"10.1016\/j.biopha.2019.109704_bib0280","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/14397595.2018.1460230","article-title":"Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: final report of a 52-week, multicenter postmarketing surveillance study","volume":"29","author":"Mimori","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.biopha.2019.109704_bib0285","first-page":"1","article-title":"The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis","author":"Suto","year":"2018","journal-title":"Mod. Rheumatol."},{"issue":"9","key":"10.1016\/j.biopha.2019.109704_bib0290","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10067-015-2999-6","article-title":"Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial","volume":"34","author":"Duan","year":"2015","journal-title":"Clin. Rheumatol."},{"issue":"7","key":"10.1016\/j.biopha.2019.109704_bib0295","first-page":"19","article-title":"Observing the curative effect of different combinations of disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis","volume":"2","author":"Guo","year":"2013","journal-title":"Rheumatism and Arthritis"},{"issue":"12","key":"10.1016\/j.biopha.2019.109704_bib0300","first-page":"1586","article-title":"Short-term clinical efficacy of methotrexate combined with Iguratimod in refractory rheumatoid arthritis","volume":"28","author":"Wang","year":"2015","journal-title":"Chinese Journal of Clinical Research"},{"issue":"5","key":"10.1016\/j.biopha.2019.109704_bib0305","first-page":"406","article-title":"Effects of TCZ combined with IMD in treatment of RRA and the impacts on ESR and CRP and Ig G levels","volume":"28","author":"Liu","year":"2018","journal-title":"Medical Journal of National Defending Forces in Southwest China"},{"issue":"2","key":"10.1016\/j.biopha.2019.109704_bib0310","first-page":"141","article-title":"The effect of Iguratimod combined with Etanercept on CD4+, CD8+T cells and immunoglobulin of patients with refractory rheumatoid arthritis","volume":"34","author":"Li","year":"2018","journal-title":"Immunol. J."},{"issue":"8","key":"10.1016\/j.biopha.2019.109704_bib0315","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s00393-015-1641-y","article-title":"Iguratimod in combination with methotrexate in active rheumatoid arthritis : therapeutic effects","volume":"75","author":"Xia","year":"2016","journal-title":"Z. Rheumatol."},{"issue":"4","key":"10.1016\/j.biopha.2019.109704_bib0320","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/14397595.2018.1486939","article-title":"The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab","volume":"29","author":"Ebina","year":"2019","journal-title":"Mod. Rheumatol."},{"issue":"2","key":"10.1016\/j.biopha.2019.109704_bib0325","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/14397595.2017.1336865","article-title":"Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: a retrospective study","volume":"28","author":"Yoshikawa","year":"2018","journal-title":"Mod. Rheumatol."},{"issue":"2","key":"10.1016\/j.biopha.2019.109704_bib0330","first-page":"114","article-title":"Clinical observation of iguratimod periodically combined with methylprednisolone and methotrexate in the treatment of rheumatoid arthritis with leucopenia","volume":"48","author":"Ying","year":"2017","journal-title":"Journal of New Medicine"},{"issue":"11","key":"10.1016\/j.biopha.2019.109704_bib0335","first-page":"86","article-title":"Efficacy of Iguratimod stage combined with methylprednisolone and methotrexate in the treatment of rheumatoid arthritis with leukopenia","volume":"12","author":"T L","year":"2017","journal-title":"Chi. J. Pharm. Eco."},{"issue":"1","key":"10.1016\/j.biopha.2019.109704_bib0340","first-page":"75","article-title":"Clinical study of effectiveness and safety of Iguratimod in treating primary Sjogren\u2019s syndrome","volume":"22","author":"Wang","year":"2018","journal-title":"Chin J Dis Control Prev"},{"issue":"9","key":"10.1016\/j.biopha.2019.109704_bib0345","first-page":"915","article-title":"Comparison of the efficacy and safty of Iguratimod and hydroxychloroquine in the treatment of Sjogren\u2019s Syndrome \u25a1","volume":"16","author":"Lv","year":"2017","journal-title":"Chin J Diffic and Compl Cas"},{"issue":"8","key":"10.1016\/j.biopha.2019.109704_bib0350","first-page":"90","article-title":"Clinical observation on iguratimod combination therapy of primary siogren\uff07s syndrome","volume":"29","author":"Jiang","year":"2016","journal-title":"Clinical Misdiagnosis & Mistherapy"},{"issue":"6","key":"10.1016\/j.biopha.2019.109704_bib0355","first-page":"719","article-title":"Clinical observation on treatment of primary Sjogren\u2019s syndrome by Iguratimod","volume":"26","author":"Zhao","year":"2014","journal-title":"Med J West China"},{"issue":"7","key":"10.1016\/j.biopha.2019.109704_bib0360","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2010.79","article-title":"Pathogenesis of ankylosing spondylitis","volume":"6","author":"Tam","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"issue":"5","key":"10.1016\/j.biopha.2019.109704_bib0365","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3899\/jrheum.110955","article-title":"Interleukin 6 blockade in spondyloarthritis","volume":"39","author":"Koumakis","year":"2012","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.biopha.2019.109704_bib0370","first-page":"253","article-title":"Clinical observation on treatment of refractory ankylosing spondylitis by Iguratimod","volume":"26","author":"Qiu","year":"2016","journal-title":"Journal of Jiangsu University (Medicine Edition)"},{"issue":"1","key":"10.1016\/j.biopha.2019.109704_bib0375","first-page":"118","article-title":"Observation of efficacy of iguratimod in the treatment of ankylosing spondylitis","volume":"27","author":"Zeng","year":"2016","journal-title":"Hainan Med J"},{"issue":"13","key":"10.1016\/j.biopha.2019.109704_bib0380","first-page":"92","article-title":"Observation of short-term efficacy of iguratimod tablets in the treatment of ankylosing spondylitis","volume":"34","author":"Ma","year":"2018","journal-title":"Chinese Community Doctors"},{"issue":"1","key":"10.1016\/j.biopha.2019.109704_bib0385","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/annrheumdis-2014-205233","article-title":"Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations","volume":"74","author":"Wallace","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2019.109704_bib0390","article-title":"Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4\u2010related diseases: a prospective clinical trial","author":"Panpan Zhang","year":"2019","journal-title":"Int. J. Rheum. Dis."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219353260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219353260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T07:31:50Z","timestamp":1734334310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332219353260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":78,"alternative-id":["S0753332219353260"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2019.109704","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular mechanisms and clinical application of Iguratimod: A review","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2019.109704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"109704"}}